Collaboration and License Agreements - Narrative (Details)						1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 16, 2021 USD ($)	May 26, 2021 USD ($)	Dec. 26, 2020 USD ($)	Mar. 31, 2020 USD ($)	Mar. 30, 2020 USD ($)	Dec. 31, 2020 USD ($)	Apr. 30, 2020 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Jul. 31, 2021 USD ($)	Mar. 31, 2021 USD ($) milestone
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additions										$ 0
Amounts due to Pfizer								$ 37,727,000		37,727,000			$ 37,727,000		$ 1,954,000
Pfizer collaboration revenue								25,172,000	$ 1,379,000	79,853,000	$ 1,379,000
Cost share advance from Pfizer										(68,654,000)	138,800,000
Shared costs										68,654,000
Richter license and milestone revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues								$ 0	$ 0	$ 31,667,000	33,333,000
Richter
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront payment received				$ 40,000,000
Maximum payment from regulatory milestones achieved					$ 40,000,000
Regulatory milestone payments received	$ 15,000,000				25,000,000
Maximum payment from sales-related milestones achieved					107,500,000
Remaining transaction price					$ 50,000,000
Additions to deferred revenue							$ 10,000,000
Percentage of performance obligation satisfied								66.66%		66.66%			66.66%
Richter | Revenue Recognized Upon Completion of Delivery
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenues								$ 16,700,000		$ 16,700,000	$ 33,300,000
Pfizer
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum payment from regulatory milestones achieved			$ 100,000,000											$ 100,000,000
Maximum payment from sales-related milestones achieved			$ 3,500,000,000
Additions to deferred revenue		$ 100,000,000
Percentage of revenue recognized			100.00%
Upfront payment received						$ 650,000,000
Maximum payment from milestones achieved			$ 3,700,000,000
Number of regulatory milestones | milestone															2
Maximum aggregate payment from milestones achieved			200,000,000
Costs covered by company													$ 100,000,000
Additions			$ 150,000,000
Repayment period			2 years
Reduction in cost share advance from implied financing costs			$ 3,600,000
Deferred revenue, recognition period			6 years
Amounts due to Pfizer								37,700,000		37,700,000			37,700,000		$ 1,900,000
Amounts due to collaboration partner, share of profits								$ 12,100,000		$ 12,100,000			$ 12,100,000		$ 1,800,000
Percentage of revenue recognized by counterparty								50.00%		50.00%			50.00%		50.00%
Amounts due to collaboration partner, reimbursement of allowable expenses								$ 25,600,000		$ 25,600,000			$ 25,600,000		$ 100,000
Pfizer collaboration revenue										(79,800,000)
Cost share advance from Pfizer										$ 66,900,000
Percentage of reimbursement of Allowable Expenses										50.00%
Shared costs										$ 68,700,000
Accretion of implied financing costs										1,800,000
Pfizer | Forecast
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Costs covered by company												$ 50,000,000
Pfizer | R&D expense
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shared costs										23,500,000
Pfizer | SG&A expense
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shared costs										$ 45,200,000